Platinum
drugOn this page
Also known as C.i. 77795Metallic platinumPlatina lPlatinum blackPlatinum metallicumPlatinum powderelementalPT
Summary
Platinum (CHEMBL1235478) is a phase-3 clinical-stage small molecule; indicated across 11 conditions including non-small cell lung carcinoma and lung neoplasm.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 11 conditions
- Clinical trials: 55
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1235478 |
| Name | Platinum |
| Type | Small molecule |
| Max phase | 3 |
Also known as: C.i. 77795, Metallic platinum, Platina l, Platinum, Platinum black, Platinum metallicum, Platinum powder, elemental, PT, PLATINUM
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| non-small cell lung carcinoma | 3 | MONDO:0005233 | EFO:0003060 |
| lung neoplasm | 3 | MONDO:0021117 | MONDO:0008903 |
| hypopharyngeal carcinoma | 3 | MONDO:0005216 | EFO:0002938 |
| small cell lung carcinoma | 2 | MONDO:0008433 | EFO:0000702 |
| breast neoplasm | 2 | MONDO:0021100 | EFO:0003869 |
| triple-negative breast carcinoma | 2 | MONDO:0005494 | EFO:0005537 |
| salivary gland cancer | 2 | MONDO:0004669 | MONDO:0000521 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 55.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 28 |
| PHASE3 | 9 |
| Not specified | 6 |
| PHASE1 | 5 |
| PHASE1/PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT06820255 | PHASE4 | RECRUITING | DDR Genes Alteration and Response to Platinum-based Chemotherapy in Advanced Urothelial Cancer. |
| NCT06951841 | PHASE4 | NOT_YET_RECRUITING | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction |
| NCT03731442 | PHASE3 | RECRUITING | Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients |
| NCT04624204 | PHASE3 | ACTIVE_NOT_RECRUITING | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) |
| NCT06870565 | PHASE3 | NOT_YET_RECRUITING | Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma |
| NCT00807066 | PHASE3 | COMPLETED | Randomized Gefitinib Trial |
| NCT01028417 | PHASE3 | COMPLETED | Study to See if Microcoil Insertion Reduces the Rate of Open Thoracotomy for Removal of Lung Nodules |
| NCT01769066 | PHASE2/PHASE3 | COMPLETED | Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC |
| NCT01951469 | PHASE3 | UNKNOWN | Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer |
| NCT01951482 | PHASE3 | COMPLETED | Pemetrexed/Platinum With or Without Bevacizumab in Brain Metastases From Patients With EGFR/ALK Negative Non-Squamous Non-small Cell Lung Cancer |
| NCT03607539 | PHASE3 | COMPLETED | Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC |
| NCT04502641 | PHASE3 | UNKNOWN | Induction Chemotherapy in Locally Advanced Hypopharyngeal Carcinoma: a Randomised Phase 3 Trial |
| NCT03916627 | PHASE2 | ACTIVE_NOT_RECRUITING | Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients |
| NCT04335292 | PHASE2 | RECRUITING | Osimertinib Then Chemotherapy in EGFR-mutated Lung Cancer with Osimertinib Third-line Rechallenge |
| NCT05500092 | PHASE2 | ACTIVE_NOT_RECRUITING | An Open Label, Randomized Study of Neoadjuvant Nivolumab and Chemotherapy, With or Without Sub-ablative Stereotactic Body Radiation Therapy, for Resectable Stage IIA to IIIB Non-small Cell Lung Cancer |
| NCT05624099 | PHASE2 | RECRUITING | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. |
| NCT05745350 | PHASE2 | RECRUITING | First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC |
| NCT05765084 | PHASE1/PHASE2 | RECRUITING | Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma |
| NCT05844150 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
| NCT06128460 | PHASE2 | NOT_YET_RECRUITING | Adjuvant Chemoradiotherapy Followed by Zimberelimab for Locally Advanced Cervical Cancer. |
| NCT06142617 | PHASE2 | NOT_YET_RECRUITING | A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation. |
| NCT06145308 | PHASE2 | RECRUITING | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
| NCT06256237 | PHASE2 | RECRUITING | Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial |
| NCT06355037 | PHASE2 | RECRUITING | Dasatinib Combined With Quercetin to Reverse Chemo Resistance in Triple Negative Breast Cancer |
| NCT06648200 | PHASE2 | NOT_YET_RECRUITING | Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer |
| NCT06769126 | PHASE2 | RECRUITING | Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study |
| NCT06969027 | PHASE2 | RECRUITING | JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC |
| NCT06977074 | PHASE2 | RECRUITING | PROPHET Study: ctDNA-Guided Personalized Induction Immunochemotherapy for NSCLC |
| NCT07097948 | PHASE2 | NOT_YET_RECRUITING | Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 |
| NCT07272590 | PHASE1/PHASE2 | NOT_YET_RECRUITING | Study of QLC5513 in Combination With Epalolimab Tovolimab (QL1706) ± Platinum in Patients With Advanced or Metastatic Malignant Solid Tumors |
| NCT07376499 | PHASE2 | NOT_YET_RECRUITING | Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction |
| NCT07497074 | PHASE2 | NOT_YET_RECRUITING | JSKN033 Combination Therapy in Subjects With Advanced Cervical Cancer |
| NCT07510594 | PHASE2 | NOT_YET_RECRUITING | A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC |
| NCT00112346 | PHASE2 | COMPLETED | Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer |
| NCT01844791 | PHASE2 | COMPLETED | An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients |
| NCT02233205 | PHASE1/PHASE2 | UNKNOWN | Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System |
| NCT02489409 | PHASE2 | UNKNOWN | Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer |
| NCT03224221 | PHASE2 | UNKNOWN | Apatinib Combined With Chemotherapy for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment |
| NCT03393507 | PHASE2 | UNKNOWN | A Study of Apatinib Treatment in for Advanced Ovarian Cancer |
| NCT03989336 | PHASE2 | COMPLETED | A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).